Bill
SB 1658
SB 1658 requires sheriffs and the Department of Corrections to provide an opioid antagonist to certain inmates at release to cut post‑release overdose deaths.
Status & Procedural History
- Introduced: Feb 2025 (filed Feb 5 / Feb 26, 2025 in various records); currently pending committee action (Rule 3‑9(a) / re‑referred to Assignments per provided status).
- Jurisdiction: Text provided corresponds to an Illinois bill (SB 1658) that amends the Counties Code and the Unified Code of Corrections.
- Legislative note: The bill language adds a new county provision and amends release procedures in the Department of Corrections’ statutes.
Purpose / Intent
- Require correctional authorities to provide an opioid antagonist (commonly naloxone) to certain people at the time of release from custody, with the goal of reducing post‑release opioid overdose deaths among people at elevated risk.
Key Provisions
- Counties Code (new section): Upon release from a county correctional institution, the sheriff must provide an opioid antagonist to the person if the person was incarcerated for drug‑related charges or was identified as having a substance‑use disorder.
- Unified Code of Corrections (amendment to Sec. 3‑14‑1): Mirrors/adds to existing release‑from‑institution provisions by requiring the Department of Corrections to include an opioid antagonist as part of the release process for persons meeting the drug‑related or substance‑use disorder criteria.
- Scope: Applies to releases from county jails/correctional institutions and State Department of Corrections facilities.
- No specific product, dosage, method of administration, consent process, training requirement, or funding mechanism is specified in the text excerpts provided.
Who Would Be Affected
- Primary obligations: County sheriffs (county jails) and the State Department of Corrections (for state prisoners).
- Primary beneficiaries: People being released from jail or prison who (a) were incarcerated for drug‑related charges or (b) were identified in custody as having a substance‑use disorder.
- Secondary impacts: County and state correctional budgets, jail release procedures, medical and reentry staff workload, and local public health programs that may coordinate distribution or training.
Potential Impacts and Considerations
- Public‑health benefit: Expected to reduce risk of fatal opioid overdose in the high‑risk post‑release period by increasing access to naloxone at the moment of community reentry.
- Fiscal impact: The bill imposes an operational requirement on sheriffs and the Department of Corrections and would likely increase costs for purchasing opioid antagonists and establishing distribution protocols. The bill header indicates it “may require reimbursement” under state mandates law — suggesting counties may seek state reimbursement for costs.
- Implementation details left to agencies: The bill does not provide explicit funding, training, recordkeeping, consent procedures, or specifications regarding the form of opioid antagonist (intranasal, injectable, kit), which could affect rollout speed and cost.
- Legal/operational issues: Agencies will need to screen/review release populations to identify eligible persons and develop intake/release workflows to provide the medication and information on its use.
Sunset / Effective Date
- No effective date or sunset language appears in the provided Illinois text. (Other materials in the broader document package reference different-state bills with varying effective dates — those are not applicable to this Illinois provision unless enacted language specifies otherwise.)
Bottom line
SB 1658 would make it mandatory for sheriffs and the Department of Corrections to give an opioid antagonist to persons released from custody if they were incarcerated on drug‑related charges or identified as having a substance‑use disorder. The measure aims to reduce post‑release overdose deaths but would require corrections systems to implement new screening and distribution processes and to absorb purchasing and administrative costs unless additional funding or reimbursement is provided.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
